Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)
Citations Over TimeTop 10% of 2021 papers
Abstract
Renal cell carcinoma (RCC) is a malignancy of the kidney originating from the tubular epithelium. Inactivation of the von Hippel-Lindau tumor-suppressor gene (VHL) is found in most clear cell renal cell carcinomas (ccRCCs). The VHL-HIF-VEGF/VEGFR pathway, which involves the von Hippel-Lindau tumor suppressor protein (VHL), hypoxia-inducible factor (HIF), vascular endothelial growth factor (VEGF), and its receptor (VEGFR), is a well-studied therapeutic target for metastatic ccRCC. Therefore, over the past decade, anti-angiogenic agents targeting VEGFR have served as the standard treatment for metastatic RCC. Recently, based on the immunomodulatory effect of anti-VEGFR therapy, anti-angiogenic agents and immune checkpoint inhibitor combination strategies have also emerged as therapeutic strategies. These advances were made possible by the improved understanding of the VHL-HIF pathway. In this review, we summarize the historical evolution of ccRCC treatments, with a focus on the involvement of the VHL-HIF pathway.
Related Papers
- → The role of HIF1α in renal cell carcinoma tumorigenesis(2014)119 cited
- → Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma(2016)48 cited
- → Analysis of the hypoxia inducible factor 1 alpha subunit (HIF1A)-dependent transcriptome during S. aureus infection in human HepG2 hepatocellular carcinoma cells(2019)
- → Hypoxia-inducible factor 1 (HIF1A; HIF1); endothelial PAS domain protein 1 (EPAS1; HIF2A); hypoxia-inducible factor prolyl hydroxylase (EGLN2; HIF-PHD; EGLN)(2009)
- → Analysis of hypoxia inducible factor 1 alpha subunit (HIF1A)- and endothelial PAS domain protein 1 (EPAS1)-dependent transcriptomes in human HepG2 hepatocellular carcinoma cells(2019)